OakChart

BridgeBio Pharma Inc

BBIOHealthcare·Biotechnology·USA·Large·NASD·Nov 11 • 3:59 PM ET

79.54+0.87 (1.11%)
2026-11-12 05:19 CET
Market cap
15,494.47 USD m
Revenue, TTM
945.54 USD m
Net income, TTM
-592.12 USD m
Free cash flow, TTM
-369.81 USD m
EPS diluted, TTM
-3.04
P/E
-
Compare

Price

BBIO against its 20, 50 and 200-day averages
2050200beatmiss
70.0080.0090.0013.5M27.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BBIOclose 79.5420-day 71.9550-day 69.89200-day 72.7079.5452w high52w low

14.9% under the 52-week high of 93.42 on 9 Jul 2026. 52-week low 62.06 on 11 Nov 2025. Last 15 sessions, 19.1% high to low

Volume 0.85× normal · the line is the 50-bar volume average

Profile

BBIO
52-week range, 56% of the way up
62.0693.42

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

IndexRUI
Employees839
IPOJun 27, 2019
Beta0.93
ATR, 14d2.79
Rel volume0.85
Short float11.95%
Insider own10.45%
Inst own92.44%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap15.49B
Enterprise Value18.32B
Income-592.12M
Sales945.54M
Book/sh-13.29
Cash/sh7.90
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees839
IPOJun 27, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S16.39
P/B-
P/C10.07
P/FCF-
EV/EBITDA-
EV/Sales19.38
Quick Ratio2.03
Current Ratio2.09
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.04
EPS next Y-0.81
EPS next Q-0.58
EPS this Y29.15%
EPS next Y69.62%
EPS next 5Y-
EPS past 3/5Y-5.07% 0.09%
Sales past 3/5Y86.30% 127.44%
EPS Y/Y TTM27.40%
Sales Y/Y TTM167.27%
EPS Q/Q55.55%
Sales Q/Q192.60%
EarningsOct 29 AMC
EPS/Sales Surpr.22.54% 20.34%

Ownership

Insider Own10.45%
Insider Trans-2.72%
Inst Own92.44%
Inst Trans-1.15%
ROA-35.81%
ROE-
ROIC-48.56%
Gross Margin94.13%
Oper. Margin-37.34%
Profit Margin-62.62%
SMA2010.54%
SMA5013.81%
SMA2009.42%
Trades-

Technical

Shs Outstand196.00M
Shs Float174.44M
Short Float11.95%
Short Ratio7.66
Short Interest20.85M
52W High93.42 -14.85%
52W Low62.06 28.17%
Volatility4.48% 3.63%
ATR (14)2.79
RSI (14)69.59
Beta0.93
Rel Volume0.85
Avg Volume2.72M
Volume2,324,962

Performance

Perf Week2.12%
Perf Month25.66%
Perf Quarter-2.06%
Perf Half Y15.93%
Perf YTD3.99%
Perf Year19.47%
Perf 3Y193.51%
Perf 5Y66.12%
Perf 10Y-
Recom1.35
Target Price109.56
Prev Close78.67
Price79.54
Change %1.11%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 03, 2026InitiatedCCanaccord GenuityBuy$104+30.8%
May 26, 2026DowngradeRRaymond JamesOutperform → Mkt Perform
May 19, 2026InitiatedCCitigroupNeutral$82+3.1%
Apr 09, 2026InitiatedRRBC Capital MktsOutperform$100+25.7%
Mar 10, 2026InitiatedWWilliam BlairOutperform
Jan 28, 2026InitiatedBBarclaysOverweight$157+97.4%
Jan 06, 2026InitiatedMMorgan StanleyOverweight$96+20.7%
Dec 11, 2025InitiatedBBernsteinOutperform$94+18.2%
Jul 30, 2025ResumedRRaymond JamesOutperform$56-29.6%
Jul 21, 2025InitiatedTTruistBuy$66-17.0%

Peers

Mkt cap
TickerCompanyMkt cap
ALNYAlnylam Pharmaceuticals Inc21.41B
IONSIonis Pharmaceuticals Inc4.72B
ASNDAscendis Pharma A/S17.03B
BMRNBiomarin Pharmaceutical Inc11.30B
CYTKCytokinetics Inc8.15B
NTLAIntellia Therapeutics Inc1.60B
EWTXEdgewise Therapeutics Inc5.21B
RAREUltragenyx Pharmaceutical Inc1.70B
PTCTPTC Therapeutics Inc5.42B
ARWRArrowhead Pharmaceuticals Inc6.97B

Insider trading

latest 14 of 88
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Apuli MaricelChief Accounting OfficerOct 30 '26Sale72.852,000145,700120,687Nov 03 04:14 PM
Kumar NeilChief Executive OfficerSep 17 '26Sale69.0810,000690,847495,686Sep 21 06:21 PM
Kumar NeilChief Executive OfficerAug 18 '26Sale82.5334,9802,886,994243,327Aug 20 04:31 PM
Kumar NeilChief Executive OfficerAug 19 '26Sale84.0310,000840,257505,686Aug 20 04:31 PM
KUMAR HALDEA FAMILY IRREVOCABLDirectorAug 19 '26Proposed Sale82.9830,0002,489,400Aug 19 04:34 PM
NEIL KUMARDirectorAug 18 '26Proposed Sale79.8934,9802,794,552Aug 18 04:26 PM
RANDAL SCOTTDirectorAug 17 '26Proposed Sale79.8621,5011,717,070Aug 17 04:32 PM
Apuli MaricelChief Accounting OfficerJul 30 '26Sale80.062,000160,120127,401Aug 03 04:20 PM
Ellis AndreaDirectorJul 09 '26Option Exercise16.7517,167287,54739,746Jul 13 04:41 PM
Ellis AndreaDirectorJul 09 '26Sale84.0017,1671,442,02822,579Jul 13 04:41 PM
Cook Jennifer E.DirectorJul 09 '26Option Exercise24.96148,5893,708,335156,972Jul 13 04:40 PM
Cook Jennifer E.DirectorJul 09 '26Sale88.54148,58913,156,0088,383Jul 13 04:40 PM
JENNIFER COOKDirectorJul 09 '26Proposed Sale88.54148,58913,156,008Jul 09 04:22 PM
ANDREA ELLISDirectorJul 09 '26Proposed Sale84.0017,1671,442,028Jul 09 04:11 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
IWPiShares Russell Mid-Cap Growth ETFAUM: 18.09B
IWRiShares Russell Mid-Cap ETFAUM: 58.68B
IWFiShares Russell 1000 Growth ETFAUM: 116.57B
SCHMSchwab U.S. Mid-Cap ETFAUM: 15.01B

News

latest 14 of 100
  • BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026 (GlobeNewswire)
  • BridgeBio to Participate in November and December Investor Conferences (GlobeNewswire)
  • BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026 (GlobeNewswire)
  • BridgeBio Beats As Bayer Milestone Flatters The Quarter, But Slowing Attruby Adds Become The Debate Ahead Of Three PDUFAs (Earnings Whispers) +5.97%
  • BridgeBio Pharma: Q3 Earnings Snapshot (Associated Press)
  • BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates (GlobeNewswire)
  • BridgeBio Must Prove Atruvi Growth Can Outrun A Shrinking Switch Pool (Earnings Whispers)
  • BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET (GlobeNewswire)
  • BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • BridgeBio Pharma Has Lost 28% Since July: Barclays Sees 139% Upside (TIKR)
  • Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records (GlobeNewswire)
  • Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 (GlobeNewswire)
  • BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-29-0.420-0.542-0.420353.17293.4721
2026Q22026-08-10-0.780-0.576-0.778243.68220.9120
2026Q12026-05-07-0.840-0.679-0.842194.52178.0718
2025Q42026-02-24-1.000-0.713-0.996154.18146.8418
2025Q32025-10-29-0.950-0.894-0.953120.7106.5916
2025Q22025-08-05-0.950-0.793-0.955110.5787.9818
2025Q12025-04-29-0.880-0.918-0.881116.6360.1613
2024Q42025-02-20-1.400-1.120-1.3995.883.0713
2024Q32024-11-12-0.860-1.003-0.8602.731.6811
2024Q22024-08-01-0.390-0.998-0.3922.173.9613
2024Q12024-05-02-0.200-0.737-0.197211.127.2610
2023Q42024-02-22-0.960-0.869-0.9641.754.5513
2023Q32023-11-02-1.080-0.793-1.0844.093.6211
2023Q22023-08-03-0.980-0.799-0.9841.642.9911
2023Q12023-05-04-0.920-0.823-0.9181.833.2311
2022Q42023-02-23-0.920-0.838-0.9211.874.5210

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.480-2.764-2.47940.5626.81
2020FY-3.800-3.524-3.8038.2522.52
2021FY-3.900-3.700-3.89769.7278.26
2022FY-3.260-3.130-3.26377.6582.75
2023FY-3.950-3.756-3.9519.3012.29
2024FY-2.880-2.514-2.879221.9219.08
2025FY-3.780-3.441-3.781502.08496.34
2026FY--2.678--1,089
2027FY--0.814--1,660
2028FY-3.227--2,582
2029FY-7.010--3,734
2030FY-9.706--4,703

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1118104310.85279396.83
2026Q4S2026-11-0218114310.85279396.83
2026Q4S2026-10-3018104310.29279396.83
2026Q4S2026-10-291945308.37273.1396.83
2026Q4S2026-10-251945308.37273.1396.83
2026Q4S2026-10-2319116308.37273.1396.83
2026Q4S2026-10-1919116308.39273.1396.83
2026Q4S2026-10-1619125312.13273.1396.83
2026Q4S2026-10-1319116310.81273.1396.83
2026Q4S2026-10-1218116309.91273.1396.83
2026Q4S2026-10-0918125314.33273.1396.83
2026Q4S2026-10-0718125314.45273.1396.83
2026Q4S2026-10-0618125314.83273.3396.83
2026Q4S2026-10-0518125314.83273.3396.83

Estimate history

EPS, annual-0.31-1.12-2.479-3.803-3.897-3.263-3.951-2.879-3.785-3.0395
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.86-1.399-0.881-0.955-0.953-0.996-0.842-0.778-0.423
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0040.568.24969.71677.6489.303221.902502.076945.54
Period201720182019202020212022202320242025TTM
Sales, quarterly2.7325.882116.633110.565120.7154.178194.515243.676353.171
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual116.756116.756123.658122.849147.343150.626175.083190.044194.772196.005
Period201720182019202020212022202320242025MRQ
Shares, quarterly188.987190.044189.826191.163192.633194.772195.708195.284196.005
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue945.54502.08221.909.3077.6569.728.2540.560.00
Cost of Goods Sold Incl. D&A55.4823.707.556.547.806.363.092.500.00
Gross Profit890.05478.38214.352.7669.8463.365.1638.060.00
Selling, General and Administrative Excl. Other1,243.16980.44791.72602.21538.28639.99479.64304.30183.66
Research and Development536.01451.95506.46455.71399.46451.02337.05209.95140.07
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-353.11-502.06-577.37-599.44-468.44-576.63-474.48-266.24-183.66
Interest Expense213.29178.2499.2981.2980.4446.7836.668.772.55
Unusual Expense-4.5622.8542.20-1.7255.72-33.261.471.07-18.20
Net Income Before Taxes-576.47-732.50-542.19-653.25-484.65-586.45-505.49-288.58-169.45
Income Taxes1.110.431.150.000.000.000.000.000.00
Consolidated Net Income-577.58-732.94-543.35-653.25-484.65-586.45-505.49-288.58-169.45
Net Income From Continuing Operations-565.83-724.93-535.76-643.20-481.18-562.54-448.72-260.59-130.75
Net Income-592.12-724.93-535.76-643.20-481.18-562.54-448.72-260.59-130.75
EPS (Recurring)-3.04-3.70-2.72-3.96-3.00-4.06-3.79-2.47-1.23
EPS (Basic, Before Extraordinaries)-3.04-3.79-2.88-3.95-3.26-3.90-3.80-2.48-1.12
EPS (Diluted)-3.04-3.79-2.88-3.95-3.26-3.90-3.80-2.48-1.12
EBITDA-348.36-496.63-571.29-592.95-461.67-570.79-471.39-266.24-183.66
Non-Operating Income (Expense)-14.63-29.35176.6625.76119.943.707.12-12.51-1.44
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense136.94108.1489.95115.0293.83105.5758.4621.376.07
Price To Sales Ratio13.6429.1823.01706.4314.4734.541,017.1790.82-
Gross Margin94.1395.2896.6029.7089.9590.8862.5793.84-
Operating Margin-37.34-100.00-260.19-6,443.56-603.28-827.12-5,751.99-656.41-
Net Margin-62.62-144.39-241.44-6,913.92-619.70-806.90-5,439.74-642.47-
Shares Outstanding196.00194.77190.04175.08150.63147.34122.85123.66116.76
Market Capitalization15,494.4715,494.475,185.897,023.051,139.062,455.058,725.414,331.304,379.50

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue353.17243.68194.51154.18120.70110.56116.635.88
Cost of Goods Sold Incl. D&A20.8215.4010.438.847.264.273.322.85
Gross Profit332.35228.28184.09145.34113.44106.30113.313.03
Selling, General and Administrative Excl. Other343.99335.36290.05273.77249.80239.77217.11224.37
Research and Development143.51149.45126.64116.42112.87111.23111.43130.35
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-11.64-107.08-105.96-128.43-136.36-133.47-103.80-221.33
Interest Expense55.5454.6252.8150.3111.7437.6442.1429.82
Unusual Expense-1.40-3.50-2.202.543.24-0.6917.734.69
Net Income Before Taxes-59.27-155.89-166.56-194.75-186.48-181.66-169.61-266.24
Income Taxes1.230.000.00-0.12-1.542.100.001.15
Consolidated Net Income-60.50-155.89-166.56-194.63-184.94-183.76-169.61-267.39
Net Income From Continuing Operations-56.71-152.22-164.04-192.86-182.74-181.90-167.42-265.05
Net Income-83.00-152.22-164.04-192.86-182.74-181.90-167.42-265.05
EPS (Recurring)-0.43-0.79-0.85-0.99-0.94-0.96-0.82-1.38
EPS (Basic, Before Extraordinaries)-0.42-0.78-0.84-1.00-0.95-0.95-0.88-1.40
EPS (Diluted)-0.42-0.78-0.84-1.00-0.95-0.95-0.88-1.40
EBITDA-10.57-106.03-104.77-127.00-134.96-132.16-102.52-219.97
Non-Operating Income (Expense)6.512.31-9.98-13.47-35.14-11.24-5.94-10.39
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense31.4944.5233.3627.5627.8629.5029.3928.78
Price To Sales Ratio13.6420.4524.9429.4928.1734.8951.5923.43
Gross Margin94.1193.6894.6494.2793.9896.1497.1551.53
Operating Margin-3.30-43.94-54.47-83.30-112.97-120.72-89.00-3,762.90
Net Margin-23.50-62.47-84.33-125.09-151.40-164.52-143.55-4,506.12
Shares Outstanding196.00195.28195.71194.77192.63191.16189.83190.04
Market Capitalization15,494.4714,587.7314,396.2714,740.319,929.278,199.066,574.835,185.89

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments588.03681.23451.54509.85836.84607.09545.99436.0992.00
Short Term Receivables139.444.721.7517.0819.750.000.000.000.00
Inventories26.750.000.000.000.000.000.000.000.00
Other Current Assets43.5234.7424.3021.9232.2735.7322.639.145.14
Total Current Assets797.75720.69477.59548.85888.86642.82568.62445.2297.13
Net Property, Plant & Equipment13.5212.7819.8425.2545.9736.835.621.570.44
Total Investments and Advances81.44145.763.742.872.422.6031.5717.210.38
Intangible Assets28.0823.9326.3228.7144.93----
Other Assets15.2416.1818.8817.3630.6121.3325.860.930.09
Total Assets936.02919.34546.38623.041,012.79703.59631.68464.9498.04
Short Term Debt Incl. Current Port. of LT Debt17.414.654.133.675.235.258.000.000.00
Accounts Payable36.239.6210.6511.5611.888.958.8513.511.89
Other Current Liabilities234.33140.13129.06106.19117.9581.4543.5319.076.67
Total Current Liabilities287.97154.40143.84121.43135.0795.6560.3832.588.55
Long Term Debt2,711.312,205.171,735.711,719.891,722.48490.5391.7954.51143.87
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities13.3217.389.3626.6420.829.523.530.490.31
Total Liabilities3,012.612,376.951,888.911,867.961,878.37595.70155.7087.58152.73
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.003.41
Common Equity-2,086.61-1,467.90-1,354.26-1,254.62-870.4157.91408.45314.88-61.43
Total Shareholders Equity-2,086.61-1,467.90-1,354.26-1,254.62-870.4157.91408.45314.88-58.02
Accumulated Minority Interest10.0310.2911.729.694.8349.9867.5262.483.33
Total Equity-2,076.58-1,457.61-1,342.54-1,244.92-865.58107.89475.98377.36-54.69
Total Liabilities & Stockholders Equity936.02919.34546.38623.041,012.79703.59631.68464.9498.04
Book Value Per Share-10.71-7.72-7.73-8.33-5.910.473.302.70-0.53
Tangible Book Value Per Share-10.86-7.85-7.89-8.52-6.210.473.302.70-0.53
Full-Time Employees839730550396576385248152-
Price to Book Ratio-5.99-4.22-5.82-1.00-2.82150.8610.619.05-
Return on Assets-78.14-73.11-110.00-58.83-65.55-67.21-47.53-46.45-
Return on Equity------192.44-213.19-101.80-
Return on Invested Capital-116.04-72.67-168.62-103.42-66.02-81.82-52.09-35.40-35.60
Quick Ratio2.684.673.324.526.586.729.4213.6711.36
Current Ratio2.774.673.324.526.586.729.4213.6711.36

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-577.58-732.94-543.35-653.25-484.65-586.45-562.25-316.58-208.15
Depreciation4.745.436.086.496.775.843.09-0.24
Other Funds (Non Cash)365.39332.66-15.50113.9830.3187.07144.5273.9149.02
Funds from Operations-207.44-394.85-552.77-532.78-447.57-493.54-414.65-242.67-159.13
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-161.53-51.0632.045.0628.08-4.4014.93-10.9122.49
Cash from Operating Activities-368.97-445.91-520.73-527.72-419.49-497.93-399.71-253.59-136.64
Capital Expenditures-0.83-9.59-8.91-1.31-6.32-48.25-7.52-5.14-18.18
Net Assets From Acquisitions0.000.000.000.000.00-85.09-5.00-55.01-44.23
Sale of Fixed Assets and Businesses0.602.150.000.00120.003.5026.2449.5258.47
Purchase or Sale of Investments-1.76-17.2044.1555.84339.47-166.23-38.720.000.00
Purchase of Investments-81.26-28.20-114.08-137.26-193.06-643.27-287.850.000.00
Sale Or Maturity of Investments79.5011.00158.23193.11532.52477.04249.140.000.00
Other Uses0.000.00-0.14-0.500.000.00-6.910.00-2.86
Other Sources0.002.3025.680.000.0013.650.000.00-
Cash from Investing Activities-1.99-22.3460.7854.03453.15-282.42-31.90-10.63-6.80
Cash Dividends Paid-2.690.000.000.000.000.000.000.000.00
Change in Capital Stock736.71-14.13322.90459.228.08-179.54-61.59368.95430.97
Repurchase of Common Pref Stock-252.50-48.280.000.000.00-200.00-75.710.000.00
Sale of Common Pref Stock989.2134.15322.90459.228.0820.4614.13368.95430.97
Proceedsfrom Stock Options938.976.41319.24453.217.413.821.21367.16430.53
Issuance or Reduction of Debt, Net548.20385.50433.080.00-20.491,063.61536.96-175.7856.34
Change in Long Term Debt548.20385.50433.080.00-20.491,063.61536.9637.1256.34
Issuance of Long Term Debt607.24859.96906.500.000.001,187.73536.9637.1257.44
Reduction of Long Term Debt-59.04-474.46-473.420.00-20.49-124.120.000.00-1.10
Net Financing Active Other Cash Flow-20.86-14.23-7.53-7.68-0.72-66.04-49.28-1.000.00
Other Financing Activities Uses-20.86-14.23-7.53-7.68-1.56-66.04-49.28-1.000.00
Cash from Financing Activities1,261.36357.14748.46451.54-13.13818.04426.10192.17487.31
Net Change in Cash890.39-111.10288.51-22.1520.5237.69-5.52-72.05343.87
Free Cash Flow-369.81-447.01-521.66-529.03-425.81-511.18-407.23-256.23-138.82
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,539.40720.71940.74588.03646.07757.34
Short Term Receivables375.09254.48205.23139.44116.5276.87
Inventories59.7252.8432.9826.7524.5318.28
Other Current Assets70.3965.1062.3643.5252.2759.79
Total Current Assets2,044.611,093.141,241.31797.75839.38912.28
Net Property, Plant & Equipment20.7922.3022.1713.5212.3812.29
Total Investments and Advances49.3656.6763.1181.4494.19109.70
Intangible Assets25.9226.6427.3628.0828.8029.51
Other Assets21.1118.5417.0415.2423.5016.41
Total Assets2,161.791,217.301,370.98936.02998.251,080.19
Short Term Debt Incl. Current Port. of LT Debt586.51580.55573.4117.4113.899.59
Accounts Payable88.2627.2029.0636.2318.7026.13
Income Tax Payable-----2.10
Other Current Liabilities302.47282.89213.90234.33184.00138.03
Total Current Liabilities977.24890.65816.37287.97216.60175.85
Long Term Debt2,827.682,821.882,811.482,711.312,690.572,667.54
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities10.3710.6612.0113.3213.8115.21
Total Liabilities3,815.293,723.193,639.863,012.612,920.982,858.61
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value942.480.000.000.000.000.00
Common Equity-2,604.82-2,515.22-2,278.36-2,086.61-1,933.07-1,787.86
Total Shareholders Equity-1,662.34-2,515.22-2,278.36-2,086.61-1,933.07-1,787.86
Accumulated Minority Interest8.849.329.4910.0310.349.44
Total Equity-1,653.51-2,505.89-2,268.88-2,076.58-1,922.73-1,778.42
Total Liabilities & Stockholders Equity2,161.791,217.301,370.98936.02998.251,080.19
Book Value Per Share-13.29-12.88-11.64-10.71-10.03-9.35
Tangible Book Value Per Share-13.42-13.02-11.78-10.86-10.18-9.51
Full-Time Employees---839--
Price to Book Ratio-5.99-6.40-6.93-7.62-5.55-4.97
Return on Assets-35.81-60.23-64.06-78.14-95.85-82.84
Return on Invested Capital-4.87-49.64-30.77-30.87-24.12-20.68
Quick Ratio2.031.171.482.683.765.08
Current Ratio2.091.231.522.773.885.19

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-60.50-155.89-166.56-194.63-184.94-183.76
Depreciation1.071.051.191.441.401.32
Other Funds (Non Cash)92.3693.0392.8387.1777.9082.34
Funds from Operations32.93-61.81-72.54-106.03-105.64-100.10
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-77.10-9.29-124.7449.61-3.9319.42
Cash from Operating Activities-44.17-71.10-197.28-56.42-109.57-80.68
Capital Expenditures-0.29-0.44-0.07-0.03-2.87-5.09
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.600.001.55
Purchase or Sale of Investments36.9018.33-42.67-14.325.03-7.91
Purchase of Investments0.00-11.27-52.67-17.32-2.97-7.91
Sale Or Maturity of Investments36.9029.6010.003.008.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.002.300.00
Cash from Investing Activities36.6117.89-42.73-13.754.46-11.45
Cash Dividends Paid-2.690.000.000.000.000.00
Preferred Dividends (Cash Flow)-2.690.000.000.000.000.00
Change in Capital Stock900.22-122.28-54.4513.218.028.94
Repurchase of Common Pref Stock-42.50-127.50-82.500.000.001.78
Sale of Common Pref Stock942.725.2228.0513.218.027.16
Proceedsfrom Stock Options932.560.000.006.410.000.00
Issuance or Reduction of Debt, Net-29.43-22.22608.41-8.56-5.89296.13
Change in Long Term Debt-29.43-22.22608.41-8.56-5.89296.13
Issuance of Long Term Debt0.00-0.43619.70-12.03-1.00297.99
Reduction of Long Term Debt-29.43-21.79-11.293.47-4.89-1.86
Net Financing Active Other Cash Flow-5.09-4.27-4.07-7.43-3.02-4.57
Other Financing Activities Uses-5.09-4.27-4.07-7.43-3.02-3.77
Cash from Financing Activities863.01-148.77549.89-2.78-0.89300.49
Net Change in Cash855.45-201.98309.88-72.96-106.00208.36
Free Cash Flow-44.46-71.54-197.35-56.45-110.04-81.28

Revenue breakdown

License and Service2024: 218.85M 2025: 128.32M
Product2024: 2.88M 2025: 362.37M
Royalty2024: 169.00K 2025: 11.39M
United States2024: 221.90M 2025: 502.08M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.95%20.8M174.4M2.57M
2026-10-1511.42%20.0M175.1M2.40M
2026-09-3011.24%19.7M175.1M2.75M
2026-09-1512.31%21.5M175.1M3.05M
2026-08-3112.48%21.8M175.1M3.19M
2026-08-1413.32%23.3M175.1M3.31M
2026-07-3113.80%23.3M169.2M3.40M
2026-07-1515.22%25.8M169.2M3.63M
2026-06-3014.25%24.1M169.2M3.10M
2026-06-1515.03%25.4M169.1M2.48M
2026-05-2914.43%24.4M169.1M2.42M
2026-05-1514.30%24.2M169.0M2.54M
2026-04-3014.29%24.0M168.2M2.70M
2026-04-1513.62%22.7M166.5M2.63M
2026-03-3114.06%23.4M166.2M2.87M
2026-03-1314.14%23.5M166.2M2.90M
2026-02-2713.21%22.0M166.2M2.73M
2026-02-1312.73%21.2M166.2M2.58M
2026-01-3012.13%20.0M164.7M2.31M
2026-01-1511.15%18.4M164.7M2.37M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call35.0042.5046.6039.754.4546.000.000.974-0.1340.007
call37.5040.0044.1046.824.1361.000.000.972-0.1330.008
call40.0037.5041.6034.803.8978.000.000.970-0.1320.008
call42.5035.0039.1042.503.5623.000.000.967-0.1300.009
call45.0032.5036.6021.233.3003010.000.964-0.1280.010
call47.5030.0034.1031.003.0527.000.000.961-0.1260.010
call50.0027.5031.6025.632.8162790.000.958-0.1240.011
call55.0022.5026.6012.152.3746.000.000.950-0.1200.013
call57.5020.0024.2034.802.2030.000.000.944-0.1170.014
call60.0017.5021.7014.951.99847.000.000.938-0.1140.015
call62.5015.1019.105.801.76566.000.000.926-0.1180.017
call65.0012.6015.2014.001.0478110.000.903-0.1350.021
call67.5010.1014.208.531.4403110.000.889-0.1280.023
call70.007.7011.608.851.1922293.000.871-0.1200.026
call72.505.409.604.201.12743.000.000.836-0.1190.031
call75.003.906.404.900.7599141.000.703-0.2040.043
call77.502.505.004.520.7914020.000.620-0.1880.047
call80.001.754.001.900.84732622.000.507-0.2140.049
call82.500.053.201.050.89536.000.000.426-0.2480.049
call85.000.451.350.500.6753711.000.299-0.1770.043
call87.500.000.450.260.4983272.000.121-0.0710.025
call90.000.000.500.380.64369.000.000.120-0.0910.025
call92.500.002.151.600.7421.000.000.107-0.0970.023
call95.000.002.150.070.5452610.000.021-0.0190.006
call97.500.002.150.000.6120.000.000.019-0.0200.006
call1000.001.800.950.67629.000.000.017-0.0200.005
call1050.001.400.900.7961840.000.015-0.0210.005
call1100.002.150.990.90836.000.000.013-0.0220.004
call1150.002.150.861.0133.000.000.012-0.0220.004
call1200.002.152.001.1127.000.000.011-0.0230.004
call1250.002.150.001.2060.000.000.010-0.0230.003
call1300.002.150.001.2940.000.000.010-0.0240.003
call1350.002.150.001.3790.000.000.009-0.0240.003
put35.000.002.150.003.0990.000.00-0.026-0.1300.007
put37.500.002.150.452.8674.000.00-0.028-0.1290.008
put40.000.002.150.002.6490.000.00-0.030-0.1270.008
put42.500.002.150.002.4450.000.00-0.033-0.1250.009
put45.000.002.150.152.2523240.00-0.036-0.1230.010
put47.500.002.150.102.06920.000.00-0.039-0.1210.010
put50.000.002.150.501.8943000.00-0.042-0.1190.011
put55.000.002.150.101.5663020.00-0.050-0.1130.013
put57.500.001.550.951.41151.000.00-0.056-0.1100.014
put60.000.000.450.051.2601071.00-0.062-0.1070.015
put62.500.000.500.101.1442581.00-0.074-0.1110.017
put65.000.001.150.231.0733,3710.00-0.097-0.1280.021
put67.500.000.950.830.92229.000.00-0.111-0.1210.023
put70.000.002.251.460.7732802.00-0.129-0.1130.026
put72.500.000.650.620.62223452.00-0.164-0.1110.031
put75.000.002.153.000.8333940.00-0.297-0.1950.043
put77.500.002.101.380.6255.001.00-0.380-0.1790.047
put80.001.453.403.300.64863.001.00-0.493-0.2050.049
put82.501.956.004.800.87910.000.00-0.574-0.2380.049
put85.004.108.009.540.9501.000.00-0.701-0.1680.043
put87.506.1010.200.001.0380.000.00-0.861-0.0750.027
put90.008.5012.6013.501.1540.000.00-0.880-0.0810.025
put92.5010.9015.000.001.2570.000.00-0.893-0.0860.023
put95.0013.4017.5012.701.3770.000.00-0.979-0.0090.006
put97.5015.9020.0014.051.4890.000.00-0.981-0.0090.006
put10018.4022.5016.051.5950.000.00-0.983-0.0090.005
put10523.4027.500.001.7930.000.00-0.985-0.0090.005
put11028.4032.500.001.9750.000.00-0.987-0.0100.004
put11533.4037.500.002.1420.000.00-0.988-0.0100.004
put12038.4042.500.002.2990.000.00-0.989-0.0100.004
put12543.4047.500.002.4450.000.00-0.990-0.0100.003
put13048.4052.500.002.5830.000.00-0.990-0.0090.003
put13553.6057.500.002.7130.000.00-0.991-0.0090.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-27SCHEDULE 13GSEC
2026-10-138-KCurrent report2026-10-06SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-08-318-KCurrent report2026-08-31SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-16SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-16SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-16SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17SCHEDULE 13D/ASEC
2026-08-178-KCurrent report2026-08-13SEC
2026-08-14424B7SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-08-03SCHEDULE 13G/ASEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-24S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-07-24S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-228-KCurrent report2026-07-22SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-10SCHEDULE 13D/ASEC
2026-07-09144Filing for proposed sale of securities under Rule 144.SEC
2026-07-09144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000145.70K1
2026-0900690.85K1
2026-08003.73M2
2026-070014.76M3
2026-060014.52M7
2026-05008.76M5
2026-04006.11M3
2026-030010.34M4
2026-020011.41M8
2026-01006.04M2
2025-12008.30M4
2025-110020.39M9

Institutional holders

Manager% owned
Jupiter Topco LLC7.20%
Kohlberg Kravis Roberts & Co. L.P.6.77%
FARALLON CAPITAL MANAGEMENT, L.L.C.5.49%
BlackRock, Inc.5.25%
VIKING GLOBAL INVESTORS LP5.08%
STATE OF WISCONSIN INVESTMENT BOARD4.13%
VANGUARD CAPITAL MANAGEMENT LLC4.03%
VANGUARD PORTFOLIO MANAGEMENT LLC3.91%
WELLINGTON MANAGEMENT GROUP LLP2.71%
PICTON MAHONEY ASSET MANAGEMENT2.55%

Funds

Fund% owned
Franklin Convertible Securities Fund23.57%
Invesco Equity and Income Fund11.02%
Columbia Convertible Securities Fund10.23%
NYLIM MacKay Convertible Fund7.66%
NYLIM VP MacKay Convertible Portfolio7.14%
Janus Henderson Multi-Sector Income Fund6.85%
iShares Convertible Bond ETF6.79%
CALAMOS CONVERTIBLE & HIGH INCOME FUND6.50%
Calamos Convertible Fund6.50%
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND6.25%

OakChart. BBIO. Cached 15 minutes.